-
公开(公告)号：US20240075165A1
公开(公告)日：2024-03-07
申请号：US17988742
申请日：2022-11-16
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K48/00 , A61K9/00 , A61K9/127 , A61K9/51 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/00 , A61K39/12 , A61K39/215 , A61P31/14 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34
CPC classification number: A61K48/0066 , A61K9/0019 , A61K9/1271 , A61K9/5123 , A61K9/5146 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/0011 , A61K39/12 , A61K39/215 , A61K48/0033 , A61P31/14 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34 , A61K38/00 , A61K2039/53 , A61K2039/54 , A61K2039/545 , C12N2770/18022 , C12N2770/18034 , C12N2770/18071 , C12N2770/20034
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US20230075979A1
公开(公告)日：2023-03-09
申请号：US17698829
申请日：2022-03-18
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K39/215 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K9/51 , A61P31/14 , C12N15/11 , C12N15/67 , C12N15/88
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US12133899B2
公开(公告)日：2024-11-05
申请号：US17988742
申请日：2022-11-16
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K48/00 , A61K9/00 , A61K9/127 , A61K9/51 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/00 , A61K39/12 , A61K39/215 , A61P31/14 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34 , A61K38/00
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US20240002127A1
公开(公告)日：2024-01-04
申请号：US17920569
申请日：2021-04-16
Applicant: Pfizer Inc. , BioNTech SE
Inventor： Marjoh Nauta , Dirk Jozef Peeters , Tom Frank Steven Van Doorslaer , Advait Vijay Badkar , Ramin Darvari , Nicholas William Warne , James Jean , Danny Pierre G. Hendrikse , Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: B65D81/127 , A61K39/215 , B65D77/04 , B65D81/38
CPC classification number: B65D81/127 , A61K39/215 , A61K2039/55555 , B65D81/3813 , B65D77/0413
Abstract: The present disclosure relates to the fields of packaging, transportation, and storage of temperature-sensitive materials, such as biological and/or pharmaceutical products. Various aspects of such packaging, transportation, and storage are provided herein for ultra-low temperature materials useful for the treatment and/or prevention of disease. The present disclosure also provides packaging materials, methods of transportation, and methods of storage for maintaining biological and/or pharmaceutical materials at ultra-low temperatures in order to maintain the integrity of the materials. The present disclosure further relates to the field of RNA to prevent or treat coronavirus infection.
-
公开(公告)号：US11925694B2
公开(公告)日：2024-03-12
申请号：US17698829
申请日：2022-03-18
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61P31/14 , A61K9/00 , A61K9/127 , A61K9/51 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/00 , A61K39/12 , A61K39/215 , A61K48/00 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34 , A61K38/00
CPC classification number: A61K48/0066 , A61K9/0019 , A61K9/1271 , A61K9/5123 , A61K9/5146 , A61K31/7088 , A61K31/7105 , A61K31/711 , A61K31/7115 , A61K31/712 , A61K39/0011 , A61K39/12 , A61K39/215 , A61K48/0033 , A61P31/14 , A61P35/00 , B82Y5/00 , C12N7/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34 , A61K38/00 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/55555 , C12N2770/18022 , C12N2770/18034 , C12N2770/18071 , C12N2770/20034 , C12N2840/00
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.
-
Patent Agency Ranking
公开(公告)号：US20220273820A1
公开(公告)日：2022-09-01
申请号：US17565921
申请日：2021-12-30
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci , Gábor Boros , Azita Josefine Mahiny , Jonas Reinholz , Katalin Karikó
IPC: A61K48/00 , A61K9/127 , A61K39/215 , C12N7/00
Abstract: Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.
-
公开(公告)号：US20230265454A1
公开(公告)日：2023-08-24
申请号：US18007550
申请日：2021-06-01
Applicant: BioNTech SE , TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenber-Universitä Mainz
Inventor： Mario Perkovic , Sonja Witzel , Tim Beissert , Ugur Sahin
IPC: C12N15/86 , C12N15/113
CPC classification number: C12N15/86 , C12N15/113 , C12N2770/36143
Abstract: The present invention embraces an RNA replicon (self-amplifying RNA vector (saRNA)) that can be replicated by a replicase of a self-replicating virus, e.g., a replicase of alphavirus origin. According to the invention, translation of the replicase open reading frame is uncoupled from a 5′-terminal cap by placing translation of the replicase open reading frame under the translational control of an internal ribosome entry site (IRES). Thereby the initiation of translation depends on the molecular properties of the respective IRES, which compared to cap-dependent translation may require less or no cellular initiation factors to direct the ribosome to the translational start site. According to the invention, IRES-controlled replicase translation may allow the use of uncapped synthetic saRNA. Furthermore, the use of an IRES provides for the option to insert additional transgenes upstream to the IRES.
-
公开(公告)号：US20230073461A1
公开(公告)日：2023-03-09
申请号：US17699035
申请日：2022-03-18
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
IPC: A61K39/12 , A61K31/7105 , A61K31/7115 , A61K31/712 , A61K9/127 , A61K9/51 , A61P31/14 , B82Y5/00 , C12N15/11 , C12N15/67 , C12N15/88 , C12P19/34
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US11547673B1
公开(公告)日：2023-01-10
申请号：US17233396
申请日：2021-04-16
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci
Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.
-
公开(公告)号：US20220249704A1
公开(公告)日：2022-08-11
申请号：US17565842
申请日：2021-12-30
Applicant: BioNTech SE
Inventor： Ugur Sahin , Alptekin Güler , Andreas Kuhn , Alexander Muik , Annette Vogel , Kerstin Walzer , Sonja Witzel , Stephanie Hein , Özlem Türeci , Gábor Boros , Azita Josefine Mahiny , Jonas Reinholz , Katalin Karikó
IPC: A61K48/00 , A61P35/00 , A61K39/00 , A61K31/7088 , A61K39/12
Abstract: Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.015 seconds)
